Relaxin and fibrosis: Emerging targets, challenges, and future directions

Anthony J. Kanai, Elisa M. Konieczko, Robert G. Bennett, Chrishan S. Samuel, Simon G. Royce

Research output: Contribution to journalReview article

Abstract

The peptide hormone relaxin is well-known for its anti-fibrotic actions in several organs, particularly from numerous studies conducted in animals. Acting through its cognate G protein-coupled receptor, relaxin family peptide receptor 1 (RXFP1), serelaxin (recombinant human relaxin) has been shown to consistently inhibit the excessive extracellular matrix production (fibrosis) that results from the aberrant wound-healing response to tissue injury and/or chronic inflammation, and at multiple levels. Furthermore, it can reduce established scarring by promoting the degradation of aberrant extracellular matrix components. Following on from the review that describes the mechanisms and signaling pathways associated with the extracellular matrix remodeling effects of serelaxin (Ng et al., 2019), this review focuses on newly identified tissue targets of serelaxin therapy in fibrosis, and the limitations associated with (se)relaxin research.

Original languageEnglish (US)
Pages (from-to)66-74
Number of pages9
JournalMolecular and Cellular Endocrinology
Volume487
DOIs
StatePublished - May 1 2019

Fingerprint

Relaxin
Fibrosis
Extracellular Matrix
Tissue
Peptide Receptors
Peptide Hormones
G-Protein-Coupled Receptors
Wound Healing
Cicatrix
Animals
Inflammation
Degradation
Direction compound
Wounds and Injuries
Research

Keywords

  • Challenges and future directions
  • Emerging targets
  • Extracellular matrix
  • Fibrosis
  • RXFP1
  • Relaxin

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Biology
  • Endocrinology

Cite this

Relaxin and fibrosis : Emerging targets, challenges, and future directions. / Kanai, Anthony J.; Konieczko, Elisa M.; Bennett, Robert G.; Samuel, Chrishan S.; Royce, Simon G.

In: Molecular and Cellular Endocrinology, Vol. 487, 01.05.2019, p. 66-74.

Research output: Contribution to journalReview article

Kanai, Anthony J. ; Konieczko, Elisa M. ; Bennett, Robert G. ; Samuel, Chrishan S. ; Royce, Simon G. / Relaxin and fibrosis : Emerging targets, challenges, and future directions. In: Molecular and Cellular Endocrinology. 2019 ; Vol. 487. pp. 66-74.
@article{e2cb519c51634a949454202dfc50127c,
title = "Relaxin and fibrosis: Emerging targets, challenges, and future directions",
abstract = "The peptide hormone relaxin is well-known for its anti-fibrotic actions in several organs, particularly from numerous studies conducted in animals. Acting through its cognate G protein-coupled receptor, relaxin family peptide receptor 1 (RXFP1), serelaxin (recombinant human relaxin) has been shown to consistently inhibit the excessive extracellular matrix production (fibrosis) that results from the aberrant wound-healing response to tissue injury and/or chronic inflammation, and at multiple levels. Furthermore, it can reduce established scarring by promoting the degradation of aberrant extracellular matrix components. Following on from the review that describes the mechanisms and signaling pathways associated with the extracellular matrix remodeling effects of serelaxin (Ng et al., 2019), this review focuses on newly identified tissue targets of serelaxin therapy in fibrosis, and the limitations associated with (se)relaxin research.",
keywords = "Challenges and future directions, Emerging targets, Extracellular matrix, Fibrosis, RXFP1, Relaxin",
author = "Kanai, {Anthony J.} and Konieczko, {Elisa M.} and Bennett, {Robert G.} and Samuel, {Chrishan S.} and Royce, {Simon G.}",
year = "2019",
month = "5",
day = "1",
doi = "10.1016/j.mce.2019.02.005",
language = "English (US)",
volume = "487",
pages = "66--74",
journal = "Molecular and Cellular Endocrinology",
issn = "0303-7207",
publisher = "Elsevier Ireland Ltd",

}

TY - JOUR

T1 - Relaxin and fibrosis

T2 - Emerging targets, challenges, and future directions

AU - Kanai, Anthony J.

AU - Konieczko, Elisa M.

AU - Bennett, Robert G.

AU - Samuel, Chrishan S.

AU - Royce, Simon G.

PY - 2019/5/1

Y1 - 2019/5/1

N2 - The peptide hormone relaxin is well-known for its anti-fibrotic actions in several organs, particularly from numerous studies conducted in animals. Acting through its cognate G protein-coupled receptor, relaxin family peptide receptor 1 (RXFP1), serelaxin (recombinant human relaxin) has been shown to consistently inhibit the excessive extracellular matrix production (fibrosis) that results from the aberrant wound-healing response to tissue injury and/or chronic inflammation, and at multiple levels. Furthermore, it can reduce established scarring by promoting the degradation of aberrant extracellular matrix components. Following on from the review that describes the mechanisms and signaling pathways associated with the extracellular matrix remodeling effects of serelaxin (Ng et al., 2019), this review focuses on newly identified tissue targets of serelaxin therapy in fibrosis, and the limitations associated with (se)relaxin research.

AB - The peptide hormone relaxin is well-known for its anti-fibrotic actions in several organs, particularly from numerous studies conducted in animals. Acting through its cognate G protein-coupled receptor, relaxin family peptide receptor 1 (RXFP1), serelaxin (recombinant human relaxin) has been shown to consistently inhibit the excessive extracellular matrix production (fibrosis) that results from the aberrant wound-healing response to tissue injury and/or chronic inflammation, and at multiple levels. Furthermore, it can reduce established scarring by promoting the degradation of aberrant extracellular matrix components. Following on from the review that describes the mechanisms and signaling pathways associated with the extracellular matrix remodeling effects of serelaxin (Ng et al., 2019), this review focuses on newly identified tissue targets of serelaxin therapy in fibrosis, and the limitations associated with (se)relaxin research.

KW - Challenges and future directions

KW - Emerging targets

KW - Extracellular matrix

KW - Fibrosis

KW - RXFP1

KW - Relaxin

UR - http://www.scopus.com/inward/record.url?scp=85062966218&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85062966218&partnerID=8YFLogxK

U2 - 10.1016/j.mce.2019.02.005

DO - 10.1016/j.mce.2019.02.005

M3 - Review article

C2 - 30772373

AN - SCOPUS:85062966218

VL - 487

SP - 66

EP - 74

JO - Molecular and Cellular Endocrinology

JF - Molecular and Cellular Endocrinology

SN - 0303-7207

ER -